Parker C - Search Results

1

A four-group urine risk classifier for predicting outcomes in patients with prostate cancer.

Connell SP, Yazbek-Hanna M, McCarthy F, Hurst R, Webb M, Curley H, Walker H, Mills R, Ball RY, Sanda MG, Pellegrini KL, Patil D, Perry AS, Schalken J, Pandha H, Whitaker H, Dennis N, Stuttle C, Mills IG, Guldvik I; Movember GAP1 Urine Biomarker Consortium; Parker C, Brewer DS, Cooper CS, Clark J. Connell SP, et al. Among authors: parker c. BJU Int. 2019 Oct;124(4):609-620. doi: 10.1111/bju.14811. Epub 2019 Jun 25. BJU Int. 2019. PMID: 31106513 Free PMC article.

2

Hormonal therapy as an adjuvant to radical radiotherapy for locally advanced prostate cancer.

Parker C, Dearnaley D. Parker C, et al. BJU Int. 2003 Jan;91(1):6-8. doi: 10.1046/j.1464-410x.2003.04008.x. BJU Int. 2003. PMID: 12614240 No abstract available.

3

Active surveillance: an individualized approach to early prostate cancer.

Parker C. Parker C. BJU Int. 2003 Jul;92(1):2-3. doi: 10.1046/j.1464-410x.2003.04295.x. BJU Int. 2003. PMID: 12823371 No abstract available.

4

Early outcomes of active surveillance for localized prostate cancer.

Hardie C, Parker C, Norman A, Eeles R, Horwich A, Huddart R, Dearnaley D. Hardie C, et al. Among authors: parker c. BJU Int. 2005 May;95(7):956-60. doi: 10.1111/j.1464-410X.2005.05446.x. BJU Int. 2005. PMID: 15839912

5

Prolonging survival in prostate cancer: chemotherapy will have an important role.

Parker C, Emberton M. Parker C, et al. BJU Int. 2005 Jul;96(1):2-3. doi: 10.1111/j.1464-410X.2005.05554.x. BJU Int. 2005. PMID: 15963108 No abstract available.

6

The Scandinavian Prostate Cancer Group Study: the case for conservative management.

Parker C. Parker C. BJU Int. 2005 Nov;96(7):952-3. doi: 10.1111/j.1464-410X.2005.05794.x. BJU Int. 2005. PMID: 16225505 No abstract available.

7

A more selective approach to prostate biopsy could be a safe and effective form of prostate cancer 'prevention'.

Parker C. Parker C. BJU Int. 2007 Sep;100(3):488-90. doi: 10.1111/j.1464-410X.2007.07040.x. Epub 2007 May 29. BJU Int. 2007. PMID: 17535273 No abstract available.

8

Does active surveillance for men with localized prostate cancer carry psychological morbidity?

Burnet KL, Parker C, Dearnaley D, Brewin CR, Watson M. Burnet KL, et al. Among authors: parker c. BJU Int. 2007 Sep;100(3):540-3. doi: 10.1111/j.1464-410X.2007.07009.x. Epub 2007 Jun 5. BJU Int. 2007. PMID: 17550414

9

Prostate-specific antigen velocity in untreated, localized prostate cancer.

Venkitaraman R, Norman A, Woode-Amissah R, Dearnaley D, Horwich A, Huddart R, Parker C. Venkitaraman R, et al. Among authors: parker c. BJU Int. 2008 Jan;101(2):161-4. doi: 10.1111/j.1464-410X.2007.07175.x. Epub 2007 Sep 10. BJU Int. 2008. PMID: 17850368

10

Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study.

Vergis R, Corbishley CM, Norman AR, Bartlett J, Jhavar S, Borre M, Heeboll S, Horwich A, Huddart R, Khoo V, Eeles R, Cooper C, Sydes M, Dearnaley D, Parker C. Vergis R, et al. Among authors: parker c. Lancet Oncol. 2008 Apr;9(4):342-51. doi: 10.1016/S1470-2045(08)70076-7. Epub 2008 Mar 17. Lancet Oncol. 2008. PMID: 18343725 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

3,097 results

Search Page